Kornimate/medical-research-clean huggingface dataset:
morbidity and mortality rates among children aged 0-59 months

Conditions: Morbidity;Infant

Summary: this retrospective observational study aimed to investigate the patterns of morbidity and mortality among children under 5 years of age in the population served by kalkaal hospital. researchers analyzed 2023 data from the hospital's electronic medical records and administrative databases to identify the most common pediatric diagnoses and causes of illness and death in this community.

this study investigated the patterns of morbidity and mortality among children under 5 years of age in the population served by kalkaal hospital. the specific objectives were to: identify the most common diagnoses and causes of illness and death in the under-5 population presenting to kalkaal hospital. analyze demographic factors (e.g. age, sex) associated with certain disease profiles and health outcomes. evaluate treatment practices, health service utilization, and mortality rates for the key pediatric health issues identified. provide a comprehensive epidemiological assessment of the burden of childhood illness and mortality in this local community. methods: this was a retrospective, observational study that analyzed 2023 data from the electronic medical records and administrative databases of kalkaal hospital. the researchers extracted and analyzed the following data: outpatient department records: diagnoses, treatments, patient demographics inpatient admission records: admission diagnoses, treatments, patient outcomes (discharged, transferred, died) mortality records: causes of death for pediatric patients the data was cleaned, coded, and analyzed using statistical software. descriptive statistics were calculated to characterize the morbidity and mortality patterns. regression analyses were conducted to identify demographic and clinical factors associated with key health outcomes.

Eligibility criteria:
inclusion criteria: 1. children aged 0-59 months who were admitted to kalkaal hospital during the specified study period. 2. medical records with complete and adequate information regarding age, gender, presenting symptoms, and diagnoses. - exclusion criteria: 1. children outside the age range of 0-59 months. 2. medical records with missing or incomplete information necessary for the analysis. 3. children admitted to kalkaal hospital for reasons unrelated to the study objectives (adult patients, non-pediatric cases).
diagnostic value of icg in endometriosis

Conditions: Endometriosis; Laparoscopy; Near Infrared Fluorescence Imaging; Indocyanine Green (ICG)

Summary: this study evaluates the diagnostic value of the addition of indocyanine green and near infrared fluorescence imaging during laparoscopy in patients with suspected endometriosis.

endometriosis is a public health problem with an increasing incidence and various symptoms. surgical treatment reliefs pain and improves fertility by radically removing endometriotic lesions. however, peritoneal endometriotic lesions may vary significantly in their appearance in standard white light laparoscopy and therefore may be difficult to be identified. because endometriosis is associated with hypervascularisation the visualization of tissue perfusion by additional use of near infrared (nir) fluorescence imaging with indocyanine green (icg) may improve the detection of peritoneal endometriotic lesions.

Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * be premenopausal (menopause is defined as amenorrhea lasting one year or longer) * patients should be in follicular phase * have chronic pelvic pain and/or infertility and be willing to undergo planned endometriosis resection procedure. exclusion criteria: * known or suspected allergy to iodine, shellfish, or icg dye * hyperthyroidism * severe renal insufficiency * simultaneous therapy with beta-blockers * women who are pregnant (positive hcg in the blood) or breast feeding * intention to become pregnant during the course of the study * inability to follow the procedures of the study (due to language problems, psychological disorders, dementia) * active pelvic infection (positive vaginal or cervical smears for bacteria or elevated markers of infection in the blood) * previous history of radiation therapy of the pelvis * presence of medical conditions contraindicating general anesthesia or standard laparoscopic surgery
assessment of the quality of sleep and sleep disorders among the professional and volunteer firefighters of loire

Conditions: Firefighter

Summary: studies have shown that schedules that most disrupt the normal circadian rhythm have the most harmful consequences. firefighters positive for a sleep disorder have a higher risk of depression and anxiety; they report more traffic accidents, falling asleep during driving, and worth health felt. furthermore, some studies suggest that sleep disorders are risk factors for cardiovascular disease. this activity is responsible of a worth quality of sleep that could induce a lower effectiveness of emergency response. the consequences of this schedules on sleep and health of french firemen have never been studied.

in this context, the objective of this observational epidemiological study is to evaluate the quality of sleep of the firefighters of loire.

Eligibility criteria:
inclusion criteria: * any professional or voluntary firefighter active in service departmental fire and rescue of loire or in retirement, and also the medical and paramedical staff of service departmental fire and rescue of loire. * any fireman affiliated to a social security regime. * any fireman who has received information from the study and has agreed to participate in the study. exclusion criteria: * any fireman unable to understand the study. * any fireman having a legal protection measure.

Keywords: firefighter sleep sleep disorders pittsburgh sleep quality index (psqi) epworth sleepiness scale insomnia severity index (isi) stop-bang questionnaire
hd-tdcs and pharmacological intervention for delirium in critical patients with covid-19

Conditions: COVID-19; Delirium; Critical Illness

Summary: the goal of this clinical trial is conducted to evaluate the efficacy and safety of active or sham hd-tdcs in combination with dexmedetomidine in patients with moderate to severe ards due to covid-19 with delirium in intensive care unit (icu). the hypothesis was that hd-tdcs combined with concomitant dexmedetomidine would reduce delirium rates.


Eligibility criteria:
inclusion criteria: * age ≥18 years, * confirmed clinical diagnosis for sars-cov-2, * delirium confirmed through the cam-icu-7 test, applied by trained evaluators exclusion criteria: * severe psychiatric illness that is not well controlled; * pregnancy or active lactation, * refusal of consent * contraindications for brain stimulation such as: aneurysm clips, pacemaker, epilepsy, dermatitis at the site of stimulation
effectiveness of interactive exergame in older adults with sarcopenia

Conditions: Sarcopenia

Summary: sarcopenia has been defined as an age related, involuntary loss of skeletal muscle mass and strength. the prevalence of sarcopenia is about 10% globally, and risk factors of sarcopenia includes age, lower physical activity, and malnutrition. sarcopenia can lead to many adverse health outcomes, particularly in physical and cognitive functions. most of previous studies have reported that interactive exergame can improve cognitive and physical functions in older population but none of studies use of interactive exergame on older adults with sarcopenia. therefore, the aim of study will investigate the effects of interactive exergame on older adults with sarcopenia.

a total of 60 older participants will be randomly assigned to the experimental and control groups. participants in the experimental group will receive 40 minutes per session, 2 times a week for 12 weeks interactive exergame while those in the control group will maintain their regular activity. all participants will be assessed their physical and cognitive function, sarcopenia index and other health related outcome measurements before and after intervention program.

Eligibility criteria:
inclusion criteria: 1. 65-99 years old 2. able to walk 6 meters without assistance devices 3. older adults with possible sarcopenia, sarcopenia or severe sarcopenia exclusion criteria: 1. people with hemodialysis 2. people with built-in electronic medical equipment 3. people with central nervous system disease such as stroke or parkinson's disease 4. score in ascertain dementia 8 more than 2 5. people with mental illness
safety and performance evaluation of the epitomee device for enhancing satiety and weight loss.

Conditions: Overweight; Obesity

Summary: study design to demonstrate the safety and performance of the epitomee device

prospective, single center, open-labeled single arm study. the subjects will be enrolled in one investigational site. subjects meeting eligibility criteria will receive multiple capsule intakes, 1 capsule twice daily for 12 weeks.

Eligibility criteria:
inclusion criteria: 1. 21 ≤ age \<65 years 2. 28 \< bmi ≤ 40 kg/m2 3. healthy subject 4. normal blood count and chemistry 5. subject is able and willing to give informed consent 6. subject is able and willing to participate in the study and follow protocol procedures exclusion criteria: a. general health and medication 1. any history or evidence of significant cardiac, renal, neurologic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease or symptom which in the judgment of the investigator would interfere with the study or confound the results 2. symptomatic or unbalanced metabolic syndrome, or, symptomatic or unbalanced type 2 diabetes - such patients with minor symptoms may be allowed according to the pi discretion 3. intake of chronic medication which may affect the gi or interrupt with the treatment, unless approved by the pi discretion 4. taking thyroid hormone deficiency drugs (such as l-thyroxine) 5. hemoglobin level under 11 gm/dl b. weight loss history and status 6. currently using pharmaceutical agents or food supplements for weight loss 7. history of weight reduction of more than 5% of total body weight in the past 6 months 8. eating disorder such as anorexia, bulimia compulsory overeating or emotional eating\* c. specific gi history and status 9. history or evidence of any active liver disease. (abnormal liver functions: \>1.5 times upper limit) 10. subject with inflammatory bowel disease (ibd) 11. significant swallowing disorders 12. less than 3 natural bowel movements per week 13. past history of any gastrointestinal surgery (excluding uncomplicated appendectomy) 14. malabsorption disorders d. general 15. history of food allergy according to pi decision 16. female subjects who are breastfeeding or have a positive pregnancy test at screening or at any time during the study 17. history of alcohol or drug abuse within 6 months of screening 18. mental disorders 19. currently participating in an ongoing clinical study

Keywords: overweight obesity
hiv acquisition and life course of born-abroad men who have sex with men living in ile-de-france: the ganymede study

Conditions: Men Who Have Sex With Men; People Living With HIV

Summary: in france, men who have sex with men (msm) born abroad are the most affected population by hiv, in terms of hiv incidence and prevalence of undiagnosed infections. close to 50% of born-abroad hiv-infected msm are living in the region of ile-de-france, which is the metropolitan area of paris. recent european data, not including france, suggest that born-abroad msm have the highest rate of post-migration hiv acquisition. many vulnerability factors could explain le burden of hiv in this group of the population. a better understanding of vulnerability factors related to post-migration hiv acquisition should allow to improve hiv prevention and screening strategies among born-abroad msm living in france. this, in turn, should reduce the burden of hiv in this population in france.

a better understanding of vulnerability factors related to post-migration hiv acquisition should allow to improve hiv prevention and screening strategies among born-abroad msm living in france. this, in turn, should reduce the burden of hiv in this population in france. multicenter, cross-sectional, two-year study in the region ile-de-france. the study is based on the self-completion of a questionnaire, built after an exploratory qualitative study. constitution of a representative sample of born-abroad hiv-infected msm from patients followed up for hiv in paris area. questionnaires will collect data needed to estimate the post-migration hiv acquisition rates, and will explore contextual and individual factors leading to high exposure to hiv. the participants will complete a questionnaire translated into 5 languages (english, spanish, portuguese, arabic, and russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. in order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service. a brief ecrf will collect clinical and biological data, and historical viral sequences in associated virology departments, when available.

Eligibility criteria:
inclusion criteria: * cis-gender men who report having sex with men; * over 18 years of age; * type 1 hiv infected; * born in a country other than france and arrived in france at the age of 15 at the earliest; * followed in ile-de-france for their hiv infection and having consulted at least once in the participating center during the last 12 months; * non-opposition to the collection of their health data, after being well informed of the study and the patient rights in accordance with rgpd and lil (french regulation) exclusion criteria: * somatic or psychiatric pathology making it impossible to participate in an investigation; * communication disorder making it impossible to read (or oral responses in the event of assisted questionnaire completion).
dysphagia and dysphonia outcomes in sars cov-2 (covid-19) infection (dyads study)

Conditions: Dysphagia; Dysphonia; Subglottic Stenosis; Voice Disorders; Swallowing Disorder; Covid19; SARS (Severe Acute Respiratory Syndrome); SARS Pneumonia; Quality of Life; SARS-CoV-2 Infection

Summary: this study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell covid-19 patient.


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with a positive sars cov-2 test. * patients who have been diagnosed with dysphonia and/or dysphagia following covid 19 treatment. * patients who require investigation and management for dysphonia and/or dysphagia following covid 19 treatment. * adult patients aged 18 years - 85 years. * patients that meet threshold for referral to the joint mdt clinic following screening exclusion criteria: * patients who cannot undertake the assessment for dysphonia and/or dysphagia. * patients who are being managed with palliative intent. * patients with pre-existing dysphonia and/or dysphagia not previously responding to therapy (pre-existing prior to covid-19 diagnosis).
effects of achieving very low ldl-cholesterol after treatment with statins on steroidogenesis and cognition

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; LDL Cholesterol; Cognition

Summary: we aimed to compare the effect of achieving an ldl-cholesterol \<70 vs an ldl-cholesterol \<100 mg/dl with simvastatin or atorvastatin on adrenal and testicular steroidogenesis, and cognition in diabetic patients.


Eligibility criteria:
inclusion criteria: * patients with controlled type 2 diabetes mellitus with overt cvd * patients with controlled type 2 diabetes mellitus over the age of 40 years without overt cvd,but with one or more major cardiovascular risk factors exclusion criteria: * uncontrolled hypertension (systolic blood pressure \>180 mm hg or diastolic blood pressure \>95 mm hg); evidence of active active liver disease or hepatic dysfunction defined as a level of liver transaminases \>2 times the upper limit of normal; uncontrolled myocardial ischaemia; congestive heart failure (new york heart association classification iiib or iv); hemodynamically important valvular disease; secondary hypercholesterolemia; gastrointestinal disease that might limit drug absorption or partial ileal bypass; myopathy, or rhabdomyolysis; a known hypersensitivity to statins; using any androgenic, estrogenic, progestogenic, antiandrogenic, or antiestrogenic agents or medications that can alter the gonadal steroid milieu; using systemic immunosuppressants or anticoagulants; plasma creatine kinase levels \>50% above the upper limit of normal,transient ischaemic attack or stroke in past,severe hypertriglyceridaemia (fasting triglyceride level ≥350 mg/dl,currently on psychotropic medications, steroids, opiate analgesics, known case of major neuropsychiatric illness,poor cognition at baseline \[mini-mental state examination(mmse) score ≤24\],physically or mentally unable to complete tests, history of other risk factors for hearing loss and/or conventional assessment that presented conductive hearing loss, confirmed by acoustic immittance measurement;presence of non-auditory associated disorders that could lead to long-latency potentials, such as neurological diseases or syndromes
clinical randomisation of an antifibrinolytic in significant haemorrhage

Conditions: Hemorrhage

Summary: crash 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. numbered drug or placebo packs will be available in each participating emergency department. randomisation will involve calling a 24-hour freecall randomisation service. the call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. for hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. no extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).

see trial website for full protocol. this is an international trial with over 300 hospitals in about 40 countries worldwide.

Eligibility criteria:
inclusion criteria: all trauma patients with ongoing significant haemorrhage (systolic blood pressure less than 90 mmhg and/or heart rate more than 110 beats per minute), or who are considered to be at risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for trial entry if they appear to be at least 16 years old. although entry is allowed up to 8 hours from injury, the earlier that patients can be treated the better. exclusion criteria: the fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular adult with traumatic haemorrhage. patients for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy should not be randomised. likewise, patients for whom there is considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps, those who have clinical evidence of a thrombotic disseminated intravascular coagulation) should not be randomised. where the responsible doctor is substantially uncertain as to whether or not to use an antifibrinolytic, all these patients are eligible for randomisation and should be considered for the trial. there are no other pre-specified exclusion criteria

Keywords: adult trauma patients with ongoing significant haemorrhage or at risk of significant haemorrhage
valuation in depressed mood, anhedonia, and anxiety

Conditions: Neurobehavioral Components of Reward and Loss Valuation

Summary: this study examines how people respond to rewards and losses, and the extent to which these responses are linked or distinct among people experiencing depressed mood, anhedonia, and/or anxiety.

this study tests relationships among neural and behavioral valuation mechanisms, and how these mechanisms change (or not) over time, with task instructions, and following cognitive behavior therapy.

Eligibility criteria:
inclusion criteria: * mood, anxiety, or anhedonia symptoms that affect functioning; fluent in english; able to see computer display; able to perform simple computer games. exclusion criteria: * history of seizure disorder, stroke, or head injury with more than 10 minutes of unconsciousness; hormone disorder; electroconvulsive therapy within 5 years; history of chemotherapy for cancer; current pregnancy; contraindications to mri

Keywords: depression anxiety anhedonia
intensive statin treatment for stemi patients undergoing primary pci

Conditions: STEMI

Summary: this is a retrospective, randomized, parallel, open-labeled, controlled study to find out whether stemi patients undergoing emergency pci can benefit from intensive atorvastatin treatment compared with routine treatment.

armyda-acs, armyda-recapture and naples ii demonstrated that in patients with asp and nste acs undergoing early pci, loading dose of atorvastatin before early pci led to a reduction of prei-pci mi, recurrent cv events and mortality. while, theses studies included patients with non-st-segment elevation acs, requiring pci; these results cannot be extrapolated directly to patients with st-segment elevation mi, and these trials included patients sent to an early and selective pci, but not those undergoing emergency revascularization; this study is designed to find out whether stemi patients undergoing emergency pci can benefit from intensive atorvastatin treatment compared with routine treatment.

Eligibility criteria:
inclusion criteria: * 20-75 years old * myocardiac ischemia symptom of index event appeared less than 12 hours before enrollment. * ecg showed elevated st segment in 3 or more contiguous leads * diagnosed with acute stemi * eligible for primary pci, and primary pci is scheduled within 2 hours after enrollment exclusion criteria: * allergic or experienced serious adverse reaction to hmg-coa reductase * pregnancy, lactation, or child bearing potential women without any effective contraception * accompanied with malignant disease * active hepatic disease or hepatic dysfunction

Keywords: stemi atorvastatin pci